<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="correction" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacokinet</journal-id><journal-title-group><journal-title>Clinical Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0312-5963</issn><issn pub-type="epub">1179-1926</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35947361</article-id><article-id pub-id-type="pmc">PMC9439970</article-id><article-id pub-id-type="publisher-id">1165</article-id><article-id pub-id-type="doi">10.1007/s40262-022-01165-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9139-8960</contrib-id><name><surname>Wallenburg</surname><given-names>Eveline</given-names></name><address><email>eveline.wallenburg@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>ter Heine</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schouten</surname><given-names>Jeroen A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Raaijmakers</surname><given-names>Jelmer</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>ten Oever</surname><given-names>Jaap</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kolwijck</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Burger</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pickkers</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Frenzel</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Br&#x000fc;ggemann</surname><given-names>Roger J. M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department of Pharmacy, Radboud University Medical Center, </institution><institution>Radboud Institute for Health Sciences, </institution></institution-wrap>864, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department of Intensive Care, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Radboud Center for Infectious Diseases (RCI), </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department of Medical Microbiology, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department of Internal Medicine, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.413508.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0501 9798</institution-id><institution>Department of Medical Microbiology, </institution><institution>Jeroen Bosch Ziekenhuis, </institution></institution-wrap>Den Bosch, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="ppub"><year>2022</year></pub-date><volume>61</volume><issue>9</issue><fpage>1325</fpage><lpage>1329</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2022</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1007/s40262-022-01113-6" id="d32e87"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Correction to: Clinical Pharmacokinetics (2022) 61:907&#x02013;918 10.1007/s40262-022-01113-6</title><p id="Par1">This is a corrigendum to Clin Pharmacokinet. 2022 Apr 4 An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients concerning a correction in the simulations of piperacillin and tazobactam concentrations with the developed pharmacokinetic model. In the original simulation dataset, by accident double doses were entered. The exposure of both piperacillin and tazobactam based on the new corrected simulations is 50% of the exposure presented in the original publication. This applies to the following sections of the article: abstract, results, discussion, conclusion, Figs. 3, 4, 5 and Tables 3 and 4. Therefore, all simulated piperacillin and tazobactam concentrations in the original manuscript should be divided by 2. The published model does not contain any errors, as the error concerns only the performed simulations. Although the main conclusion of the article remains intact, some parts of the results and discussion are subject to reinterpretation.</p><p id="Par2">In the results section it is mentioned that the target concentration for tazobactam (2.86 mg/L) was predicted to be reached in 100% of the population when tazobactam in a dose of &#x02265; 2 g/ 24 h was administered and in 99.0% and 99.4% of the population with doses of 1 and 1.5 g/24 h, respectively. Based on the new simulations the target was predicted to be reached in 99.0% of the population when a dose of &#x02265; 2 g/24 h was administered, and in 76.1% and 94.1% of the population with doses of 1 and 1.5 g/24 h, respectively.</p><p id="Par3">In the results it is mentioned that piperacillin dosed at 12 g/24 h is predicted to be sufficient to attain a target of 100% <italic>f</italic>T<sub>&#x0003e;1&#x000d7;MIC</sub> (MIC &#x02264; 16 mg/L), even for patients with a creatinine clearance of up to 200 mL/min. Based on the correct simulations a dose of 12 g/24 h is sufficient for patients with creatinine clearances &#x0003c; 150 mL/min. Patients with a creatinine clearance of 150-200 mL/min should be administered a dose of 16 g/24 h.</p><p id="Par4">In the results it is also mentioned that in case a target of 100% <italic>f</italic>T<sub>&#x0003e;5&#x000d7;MIC</sub> is desired, a piperacillin dose of 20 g/24 h is predicted to be sufficient for patients with creatinine clearances of 10-60 mL/min. Based on the correct simulations a dose of 20 g/24 h is inadequate to reach a target of 100% <italic>f</italic>T<sub>&#x0003e;5&#x000d7;MIC</sub> for patients with creatinine clearances of 10-60 mL/min.</p><p id="Par5">Concerning the piperacillin toxicity, it is mentioned in the results section that a limited fraction of 8.0% of the population is predicted to reach the putative toxicity threshold of 157 mg/L at a dose of 8 g/24 h and in 19.6% with a dose of 12 g/24 h, in 33.3% with a dose of 16 g/24 h, and in 47.8% with a dose of 20 g/24 h. Based on the corrected simulations the predicted fraction of the population reaching an exposure of 157 mg/L is 0.9% at a dose of 8 g/24 h, 3.7% with a dose of 12 g/24 h, 8.1% with a dose of 16 g/24 h, and 13.8% with a dose of 20 g/24 h.</p><p id="Par6">The corrected Figs. <xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>, <xref rid="Fig5" ref-type="fig">5</xref> and Tables <xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref> are enclosed.<fig id="Fig3"><label>Fig. 3</label><caption><p>Simulated piperacillin concentrations for different dosing regimens versus creatinine clearance. The blue horizontal lines represents a target of 100% fT&#x0003e;1xMIC (22.9 mg/L) and 100% fT&#x0003e;5xMIC (114 mg/L), assuming an MIC of 16 mg/L. The red horizontal line represents the upper limit of toxicity (157 mg/L). Simulations were performed in 20 groups of creatinine clearance between 10-200 mL/min, with 10 mL/min increments. In this table pairs of two groups have been combined</p></caption><graphic xlink:href="40262_2022_1165_Fig3_HTML" id="MO1"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Simulated tazobactam concentrations for different dosing regimens versus creatinine clearance. The blue horizontal line represents a target of 2.86 mg/L. Simulations were performed in 20 groups of creatinine clearance between 10-200 mL/min, with 10 mL/min increments. In this table pairs of two groups have been combined</p></caption><graphic xlink:href="40262_2022_1165_Fig4_HTML" id="MO2"/></fig><fig id="Fig5"><label>Fig. 5</label><caption><p>Piperacillin (left) and tazobactam (right) concentrations in urine</p></caption><graphic xlink:href="40262_2022_1165_Fig5_HTML" id="MO3"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Probability of target attainment for MIC=16 mg/L (ECOFF <italic>P. aeruginosa</italic>), and probability of reaching the potential toxicity level of 157 mg/L for different doses of piperacillin and different classes of creatinine clearance</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Creatinine clearance (mL/min)<sup>a</sup></th><th align="left">Dose piperacillin/tazobactam (g)</th><th align="left">100% <italic>f</italic>T<sub>&#x0003e;1xMIC</sub></th><th align="left">100% <italic>f</italic>T<sub>&#x0003e;5xMIC</sub></th><th align="left">Toxicity level &#x0003e;157 mg/L</th></tr></thead><tbody><tr><td align="left" rowspan="4">10&#x02013;20</td><td align="left">8/1</td><td align="left">93</td><td align="left"><bold>21</bold></td><td align="left">8.2</td></tr><tr><td align="left">12/1.5</td><td align="left">97.4</td><td align="left"><bold>47.8</bold></td><td align="left">26.2</td></tr><tr><td align="left">16/2</td><td align="left">99.4</td><td align="left"><bold>63.2</bold></td><td align="left">45.2</td></tr><tr><td align="left">20/2.5</td><td align="left">99.8</td><td align="left"><bold>73.2</bold></td><td align="left">58.4</td></tr><tr><td align="left" rowspan="4">30&#x02013;40</td><td align="left">8/1</td><td align="left">92.6</td><td align="left"><bold>5.4</bold></td><td align="left">0.6</td></tr><tr><td align="left">12/1.5</td><td align="left">98</td><td align="left"><bold>24.2</bold></td><td align="left">8.4</td></tr><tr><td align="left">16/2</td><td align="left">98.6</td><td align="left"><bold>47.4</bold></td><td align="left">22.6</td></tr><tr><td align="left">20/2.5</td><td align="left">99.2</td><td align="left"><bold>63.8</bold></td><td align="left">40.4</td></tr><tr><td align="left" rowspan="4">50&#x02013;60</td><td align="left">8/1</td><td align="left">91.2</td><td align="left"><bold>1.2</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left">97.6</td><td align="left"><bold>9.6</bold></td><td align="left">1.8</td></tr><tr><td align="left">16/2</td><td align="left">99.4</td><td align="left"><bold>29.8</bold></td><td align="left">8</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left"><bold>46.8</bold></td><td align="left">22.2</td></tr><tr><td align="left" rowspan="4">70&#x02013;80</td><td align="left">8/1</td><td align="left"><bold>87.2</bold></td><td align="left"><bold>0.4</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left">97.2</td><td align="left"><bold>4.2</bold></td><td align="left">0.6</td></tr><tr><td align="left">16/2</td><td align="left">99.2</td><td align="left"><bold>16.4</bold></td><td align="left">3.6</td></tr><tr><td align="left">20/2.5</td><td align="left">99.6</td><td align="left"><bold>31.6</bold></td><td align="left">10.6</td></tr><tr><td align="left" rowspan="4">90&#x02013;100</td><td align="left">8/1</td><td align="left"><bold>81.2</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left">95</td><td align="left"><bold>1.4</bold></td><td align="left">0</td></tr><tr><td align="left">16/2</td><td align="left">98.2</td><td align="left"><bold>7.6</bold></td><td align="left">1</td></tr><tr><td align="left">20/2.5</td><td align="left">98.8</td><td align="left"><bold>22.4</bold></td><td align="left">4.2</td></tr><tr><td align="left" rowspan="4">110&#x02013;120</td><td align="left">8/1</td><td align="left"><bold>70</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left">90.8</td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">16/2</td><td align="left">97.4</td><td align="left"><bold>2.6</bold></td><td align="left">0</td></tr><tr><td align="left">20/2.5</td><td align="left">99.6</td><td align="left"><bold>10.6</bold></td><td align="left">1.2</td></tr><tr><td align="left" rowspan="4">130&#x02013;140</td><td align="left">8/1</td><td align="left"><bold>60.8</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left">90.4</td><td align="left"><bold>0.2</bold></td><td align="left">0.2</td></tr><tr><td align="left">16/2</td><td align="left">96.6</td><td align="left"><bold>1</bold></td><td align="left">0.2</td></tr><tr><td align="left">20/2.5</td><td align="left">99.2</td><td align="left"><bold>5.8</bold></td><td align="left">0.8</td></tr><tr><td align="left" rowspan="4">150&#x02013;160</td><td align="left">8/1</td><td align="left"><bold>51.6</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left"><bold>84.6</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">16/2</td><td align="left">95.6</td><td align="left"><bold>0.2</bold></td><td align="left">0</td></tr><tr><td align="left">20/2.5</td><td align="left">99.2</td><td align="left"><bold>2.2</bold></td><td align="left">0</td></tr><tr><td align="left" rowspan="4">170&#x02013;180</td><td align="left">8/1</td><td align="left"><bold>40.6</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left"><bold>79.2</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">16/2</td><td align="left">94.8</td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">20/2.5</td><td align="left">99.4</td><td align="left"><bold>1.2</bold></td><td align="left">0</td></tr><tr><td align="left" rowspan="4">190&#x02013;200</td><td align="left">8/1</td><td align="left"><bold>37</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">12/1.5</td><td align="left"><bold>75.6</bold></td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">16/2</td><td align="left">93.4</td><td align="left"><bold>0</bold></td><td align="left">0</td></tr><tr><td align="left">20/2.5</td><td align="left">98</td><td align="left"><bold>0.8</bold></td><td align="left">0</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Simulations were performed in 20 groups of creatinine clearance between 10 and 200 mL/min, with 10 mL/min increments. In this table pairs of two groups have been combined</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Cumulative fraction of response</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Creatinine clearance (mL/min)<sup>a</sup></th><th align="left" rowspan="2">Dose piperacillin/tazobactam (g)</th><th align="left" colspan="2"><italic>E. coli</italic></th><th align="left" colspan="2"><italic>K. pneumoniae</italic></th></tr><tr><th align="left">100% <italic>f</italic>T<sub>&#x0003e;1xMIC</sub></th><th align="left">100% <italic>f</italic>T<sub>&#x0003e;5xMIC</sub></th><th align="left">100% <italic>f</italic>T<sub>&#x0003e;1xMIC</sub></th><th align="left">100% <italic>f</italic>T<sub>&#x0003e;5xMIC</sub></th></tr></thead><tbody><tr><td align="left" rowspan="4">10&#x02013;20</td><td align="left">8/1</td><td align="left">100</td><td align="left">96.0</td><td align="left">100</td><td char="." align="char">93.0</td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">99.0</td><td align="left">100</td><td char="." align="char">97.6</td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">99.0</td><td align="left">100</td><td char="." align="char">98.6</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">100</td><td align="left">100</td><td char="." align="char">98.4</td></tr><tr><td align="left" rowspan="4">30&#x02013;40</td><td align="left">8/1</td><td align="left">100</td><td align="left">95.6</td><td align="left">99.8</td><td char="." align="char">90.4</td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">97.4</td><td align="left">100</td><td char="." align="char">96.0</td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">99.0</td><td align="left">100</td><td char="." align="char">98.2</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">99.0</td><td align="left">100</td><td char="." align="char">99.0</td></tr><tr><td align="left" rowspan="4">50&#x02013;60</td><td align="left">8/1</td><td align="left">100</td><td align="left">95.8</td><td align="left">99.8</td><td char="." align="char"><bold>88.6</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">97.6</td><td align="left">100</td><td char="." align="char">93.4</td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">100</td><td align="left">100</td><td char="." align="char">98.2</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">100</td><td align="left">100</td><td char="." align="char">98.2</td></tr><tr><td align="left" rowspan="4">70&#x02013;80</td><td align="left">8/1</td><td align="left">99.8</td><td align="left">92.2</td><td align="left">99.8</td><td char="." align="char"><bold>82.6</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">96.8</td><td align="left">100</td><td char="." align="char">94.2</td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">99.4</td><td align="left">100</td><td char="." align="char">96.8</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">99.6</td><td align="left">100</td><td char="." align="char">99.0</td></tr><tr><td align="left" rowspan="4">90&#x02013;100</td><td align="left">8/1</td><td align="left">100</td><td align="left"><bold>89.8</bold></td><td align="left">99.8</td><td char="." align="char"><bold>79.6</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">95.0</td><td align="left">100</td><td char="." align="char"><bold>88.8</bold></td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">98.8</td><td align="left">100</td><td char="." align="char">95.2</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">98.4</td><td align="left">100</td><td char="." align="char">96.8</td></tr><tr><td align="left" rowspan="4">110&#x02013;120</td><td align="left">8/1</td><td align="left">100</td><td align="left"><bold>86.8</bold></td><td align="left">98.8</td><td char="." align="char"><bold>70.2</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">94.0</td><td align="left">100</td><td char="." align="char"><bold>89.0</bold></td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">97.4</td><td align="left">100</td><td char="." align="char">91.8</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">98.8</td><td align="left">100</td><td char="." align="char">96.2</td></tr><tr><td align="left" rowspan="4">130&#x02013;140</td><td align="left">8/1</td><td align="left">99.8</td><td align="left"><bold>86.6</bold></td><td align="left">99.6</td><td char="." align="char"><bold>68.4</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">93.8</td><td align="left">100</td><td char="." align="char"><bold>83.0</bold></td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">96.8</td><td align="left">100</td><td char="." align="char">92.0</td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">97.8</td><td align="left">100</td><td char="." align="char">96.0</td></tr><tr><td align="left" rowspan="4">150&#x02013;160</td><td align="left">8/1</td><td align="left">99.8</td><td align="left"><bold>82.6</bold></td><td align="left">99.4</td><td char="." align="char"><bold>63.6</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">93.0</td><td align="left">100</td><td char="." align="char"><bold>82.2</bold></td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">96.2</td><td align="left">100</td><td char="." align="char"><bold>89.2</bold></td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">97.0</td><td align="left">100</td><td char="." align="char">93.6</td></tr><tr><td align="left" rowspan="4">170&#x02013;180</td><td align="left">8/1</td><td align="left">99.6</td><td align="left"><bold>80.0</bold></td><td align="left">100</td><td char="." align="char"><bold>63.0</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left"><bold>89.4</bold></td><td align="left">100</td><td char="." align="char"><bold>79.4</bold></td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">94.0</td><td align="left">100</td><td char="." align="char"><bold>83.8</bold></td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">96.6</td><td align="left">100</td><td char="." align="char">91.0</td></tr><tr><td align="left" rowspan="4">190&#x02013;200</td><td align="left">8/1</td><td align="left">99.8</td><td align="left"><bold>79.0</bold></td><td align="left">99.4</td><td char="." align="char"><bold>55.8</bold></td></tr><tr><td align="left">12/1.5</td><td align="left">100</td><td align="left">91.2</td><td align="left">99.6</td><td char="." align="char"><bold>74.0</bold></td></tr><tr><td align="left">16/2</td><td align="left">100</td><td align="left">96.2</td><td align="left">100</td><td char="." align="char"><bold>85.6</bold></td></tr><tr><td align="left">20/2.5</td><td align="left">100</td><td align="left">96.6</td><td align="left">100</td><td char="." align="char"><bold>89.2</bold></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Simulations were performed in 20 groups of creatinine clearance between 10 and 200 mL/min, with 10 mL/min increments. In this table pairs of two groups have been combined</p></table-wrap-foot></table-wrap></p></sec></body></article>
